Neuroscience

Brain neurons in lysosomal storage diseases
#Casma Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

Casma takes a new therapeutic approach to neurodegeneration

Casma Therapeutics has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist, marking a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases.  CSM-101 is being developed for the treatment of Gaucher’s disease patients with Parkinson’s disease (GD-PD), with the potential to expand… Read More

#News

Human brain
#Mergers and acquisitions #Neuropsychiatric disorders #Neuroscience #Postpartum depression #Sage Therapeutics #Supernus Pharmaceuticals

Supernus acquires Sage to strengthen neuropsychiatry portfolio

Supernus Pharmaceuticals will acquire Sage Therapeutics through a tender offer totalling approximately $795 million.  The transaction will provide Supernus with Zurzuvae (zuranolone) capsules CIV, the only US Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression.  Through a collaboration agreement with Biogen, Supernus… Read More

#Business & Investment #News #Trending News

#AI / data analytics / healthtech / informatics #Alzheimer's #CNS #Gene editing #Human disease models #Interview #Neurodegenerative disorders #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife #Stem cells

Podcast: Unlocking neuroscience drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More

#News

Neurones in the brain
#Alzheimer's #Cell and gene therapy #Cognitive impairment #Gene therapy #Neurology #Neuroscience #University of California San Diego

Alzheimer’s gene therapy shows promise in preserving brain function

Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function. Unlike existing treatments for AD that target unhealthy protein deposits in the brain, the new approach could help address… Read More

#News

Synsapses
#Amyotrophic lateral sclerosis (ALS) #FDA #Neuroscience #Orphan drugs #Spinogenix

First synaptic regenerative therapy for ALS gets orphan status

The European Medicines Agency (EMA) has granted orphan drug designation (ODD) to Spinogenix’s SPG302 for the treatment of people living with amyotrophic lateral sclerosis (ALS).   SPG302 is being developed as the first synaptic regenerative approach for the treatment of ALS, with the potential to restore function in cognition, movement, and… Read More

#Editor's Choice #News #Regulatory

#BIAL #Biopharmaceuticals #Neuroscience #Parkinson's #Rare diseases

BIAL to present at GBA1 Meeting 2025 on Parkinson’s treatment

BIAL, a biopharmaceutical company focused on neurosciences and rare diseases, will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held 5-7 June 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1… Read More

#News

Neurones in the brain
#Neuroscience #Parkinson's #University of Queensland

Breakthrough could boost quality of life for people with Parkinson’s disease

University of Queensland researchers have found that Gherlin, the natural ‘hunger hormone’, could be the key to preventing debilitating chronic constipation experienced by people living with Parkinson’s disease. Associate Professor Sebastian Furness from the UQ School of Biomedical Sciences said the team discovered the body’s receptor for Ghrelin had a… Read More

#News

Biomarkers concept
#Biomarkers #Drug discovery #Endometriosis #Genetics / genomics #Neurodegenerative disorders #Neuroscience #Women's health

New podcast: Innovative uses for biomarkers in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “How biomarkers can help discover new treatments for women’s health” and… Read More

#News

Human neuron
#Augustine Therapeutics #Charcot-Marie-Tooth disease (CMT) #Clinical trials #Neurology #Neuroscience

First patient dosed with Charcot-Marie-Tooth disease treatment

Augustine Therapeutics has dosed the first patient in its Phase I clinical trial evaluating lead candidate AGT-100216, the first peripherally-restricted, selective cytosolic Histone DeACetylase 6 (HDAC6) inhibitor for the treatment of Charcot-Marie-Tooth disease (CMT), an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain,… Read More

#News

#Drug discovery #Events #Neuroscience #Webinar

Webinar: Hear from the experts in neuroscience drug discovery

Hosted by Drug Discovery World and sponsored by Emulate, this free webinar explores where innovation is taking place within neuroscience drug discovery.  The webinar sese experts and leaders from the neuroscience sector discuss where innovation is occurring and what the challenges are to overcome for drug… Read More

Webinar date:
Sponsored by Emulate
#News

#Alzheimer's #Mergers and acquisitions #Neurodegenerative disorders #Neurology #Neuroscience #Sanofi

Sanofi expands neurology pipeline with Vigil Neuroscience acquisition

Sanofi has entered into an agreement to acquire Vigil Neuroscience, a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.  The company says this acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances its early-stage pipeline and includes VG-3927, which will be evaluated… Read More

#Business & Investment #News #Trending News

Neuron firing
#Clinical trials #Herantis Pharma #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

First patients dosed in Phase Ib Parkinson’s disease trial

Herantis Pharma has dosed the first patients in the final cohort of its Phase Ib clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Commenting on the study, Antti Vuolanto, CEO of Herantis Pharma, said: “Parkinson’s disease is a life altering condition, and there is… Read More

#News

#Genetic diseases #Huntington's disease #Neurodegenerative disorders #Neuroscience

Tipping point in Huntington’s disease research

Jan Thirkettle, CEO of Harness Therapeutics, looks at the emerging opportunities for drug discovery and development for Huntington's disease. Huntington's disease (HD) represents one of medicine's most significant unmet needs, affecting approximately 10 in 100,000 people, with over 200,000 people at risk of inheriting the disease in the US alone. Read More

#Exclusive Content

Neurons in the brain
#Alta Neuroscience #Alzheimer's #Biomarkers #Blood-based biomarkers #Diagnostics #Roche

How Roche is advancing Alzheimer’s research

DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes.  MT: Why is improving AD diagnostics crucial… Read More

#Exclusive Content

Neuroscience concept
#Drug discovery #Events #Neuroscience #Webinar

Webinar: Where is the opportunity in neuroscience drug discovery?

Hosted by Drug Discovery World and sponsored by Emulate, this webinar explores where innovation is taking place within neuroscience drug discovery.  The webinar sees experts and leaders from the neuroscience sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects… Read More

Webinar date:
Sponsored by Emulate
#News